Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy

BACKGROUND: KRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker. OBJECTIVE: The aim of our work was to investigate the impact of KRAS mutations on response and survival outcomes in advanced non-squamous NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Veccia, Antonello, Dipasquale, Mariachiara, Kinspergher, Stefania, Monteverdi, Sara, Girlando, Salvatore, Barbareschi, Mattia, Caffo, Orazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928930/
https://www.ncbi.nlm.nih.gov/pubmed/36482151
http://dx.doi.org/10.1007/s11523-022-00934-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928930/
https://www.ncbi.nlm.nih.gov/pubmed/36482151
http://dx.doi.org/10.1007/s11523-022-00934-6

Ejemplares similares